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Abstract
Background: The anticancer drugs, such as DNA replication inhibitors, stimulate bacterial adhesion and induce the
bacterial SOS response. As a variety of bacterial mutants can be generated during SOS, novel phenotypes are likely
to be selected under the drug pressure.
Presentation of the hypothesis: Bacteria growing with cancer cells in the presence of the replication inhibitors
undergo the SOS response and evolve advantageous phenotypes for the bacteria to invade the cancer cells in
order to evade the drug attack. This hypothesis predicts that bacteria produce the proteins that mediate bacterial
capture and invasion of cancer cells–the advantageous phenotypes. Generation of the phenotypes may be
facilitated during the SOS response induced by anticancer drugs.
Testing the hypothesis: Experimental design: 1) Examine attachment and invasion of bacterium Pseudomonas
aeruginosa and the SOS mutant control to cancer cells in the presence of the anticancer drugs that inhibit DNA
replication enzymes and trigger the SOS response. 2) Reveal the bacterial proteins that exhibit changes in
expression. 3) Identify the genes encoding cancer adhesion and invasion. 4) Construct the mutants for the genes,
clone and express these genes. 5) Examine the bacterial capture and invasion of cancer cells in contrast to non-
cancer control.
Expected results: 1) The bacterial proteins will be differentially induced during bacteria-cancer interaction under the
SOS response to the anticancer drugs. 2) Knocking out the bacterial cancer-adhesion-invasion genes will disrupt
the adhesion-invasion phenotypes of the bacteria. 3) Expressing these genes will direct the bacterial capture and
invasion of cancer cells.
Implications of the hypothesis: Bacteria can evolve anticancer phenotypes targeting metastatic cells. If this
hypothesis is true, the outcomes will contribute to development of a novel bacterial anti-metastasis regimen.
Background
Attempts with live bacteria to control cancer progres-
sion were tried over a century ago [1,2]. Although unde-
sired infections raised a concern, creative hypotheses
and progress have sparkled. As reviewed by Chakrabarty
[3], antitumor treatment with Clostridium novyi was
proposed, based on propensity of the anaerobe to grow
in anaerobic core of the tumors and to deprive tumors
of oxygen and essential nutrients. Salmonella,af a c u l t a -
tive anaerobe, was also found to have tumor propensity
that appears to be encoded by the pathogenicity island.
Furthermore, bacteria could be engineered for selective
destruction of tumors and for bacterial gene-directed
prodrug therapy; in fact, such bacteria appeared to kill
tumors selectively but not the normal tissue [4]. While
these data support the notion of bacterial tropism and
cancer killing, it remains unclear how they are devel-
oped and what evolutionary relationship of bacteria is
with cancer.
We previously proposed the analogy of bacterial life-
style to cancer cell behaviors, projecting the evolutionary
relationship [5,6]. The shared features are reflected by
observations that bacteria and cancer cells respond simi-
larly to such anticancer drugs as DNA replication inhi-
bitors [5]. These common lifestyles imply that they may
compete with each other under certain conditions [5,6].
Bacteria growing under competition and drug influence
are highly likely to evolve new phenotypes against
cancer.
Replication inhibitors also induce the SOS response
[7] during which generation of new phenotype may be
facilitated. SOS is a transcriptional response, in which at
least 40 SOS genes in E. coli [8-10] and 15 in P.
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SOS regulators LexA and RecA (Fig. 1). In the presence
of single-stranded DNAs that are generated during repli-
cation inhibition, RecA coprotease senses the signals
and binds to the single-stranded DNA to assume an
active conformation [12] and to stimulate auto-cleavage
of LexA [13]. Consequently, LexA repression of the SOS
genes is prevented by this cleavage leading to a global
induction of the SOS response.
These SOS gene products are involved in cytogenesis,
DNA recombination, DNA replication, DNA damage
repair, and segregation of chromosomes during cell divi-
sion [14,15]. For instance, the SOS gene, sulA,i s
induced to inhibit and delay cell division transiently
leading to cell filamentation (Fig. 1) until DNA damage
is ameliorated. The SOS-controlled umu operon is
involved in the error-prone translesion DNA synthesis
[16]. If damage is so extensive that it cannot be directly
repaired, the lesions of damage can be bypassed by the
translesion synthesis with aid of the umu encoded pro-
teins [17], leading to mutagenesis and genetic instability.
A variety of bacterial mutants can be generated conse-
quently. If bacteria grow with cancer and anticancer
drugs, pools of these bacterial mutants are, in fact,
selected for new phenotypes (Fig. 2).
T h i sa r t i c l ea i m st op r e s e n tac r e a t i v eh y p o t h e s i sa s
below. This hypothesis predicts that bacteria can evolve
the cancer adhesion-invasion phenotypes, to challenge
the limitation of anticancer treatment arising from bac-
terial natural propensity to cancer. The outcomes should
help develop novel bacterial anticancer regimens to deal
with the safety and specificity issues poised over a cen-
tury ago.
Presentation of the hypothesis
Our hypothesis states that bacteria, growing with cancer
cells and replication inhibition drugs, evolve advanta-
geous phenotypes. This hypothesis suggests that treated
with the drugs, bacteria can be induced to adhere to
and to invade cancer cells so that bacteria survive the
drug attack. These features are defined as the cancer
adhesion-invasion phenotypes. Obviously, our hypothesis
is not based on the bacterial natural antitumor propen-
sity but on the SOS-induced molecular evolution of new
phenotypes. This hypothesis will be tested with P. aeru-
ginosa as a starter. While its ecological niche may not
be necessarily tumor, this bacterium could attach to and
penetrated human lung epithelial cells derived from a
human bronchus alveolar carcinoma [18]. These antitu-
mor activities may be mediated by bacterial proteins; in
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Figure 1 The SOS response. LexA and RecA control the SOS genes that encode functions required for DNA damage repair. LexA represses
these genes. DNA damage activates RecA to stimulate autocatalytic cleavage of LexA so that the SOS genes are derepressed and expressed for
repair. Cell division is inhibited and delayed resulting filamentation to allow repair before cell division.
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tial since it has genes encoding antitumor proteins.
Azurin is a periplasmic antitumor protein in P. aerugi-
nosa (reviewed in [19]). Release of Azurin depends on
contact with cancer cells, and Azurin targets preferen-
tially cancer cells but marginally normal cells [20]. Addi-
tionally, Laz and Pa-CARD displays cytotoxic activity
against leukemia cells [21]. Our hypothesis suggests that
such proteins and new candidates would emerge when
bacteria undergoing the anticancer drugs-induced SOS
mutagenesis interact with cancer cells.
Furthermore, bacterial adhesion to cancer may be
induced as we proposed previously [6]. P. aeruginosa
can be induced to attach to abiotic surface and can
form biofilms in response to hydroxyurea [5,22]. While
historically it is an antiproliferative drug for tumor treat-
ment [5,22], hydroxyurea is a replication inhibitor tar-
geting at ribonucleotide reductases that are a good
anticancer target [23]. This drug inhibits growth of pro-
liferating planktonic bacterial cells but stimulates bacter-
ial adhesion [5,22], likely to cancer. Such replication
inhibitors induce the bacterial SOS response (Fig. 1) [7]
during which generation of the advantageous pheno-
types may be facilitated (Fig. 2). For instance, error
prone DNA replication generates mutagenesis and
genetic instability during SOS, yielding a variety of bac-
terial mutants. Since bacterial entry into cancer cells can
evade the drug attack, these mutants can be selected for
cancer invasion for bacterial survival.
Testing the hypothesis
Experimental design
To test this hypothesis, we will first examine attachment
of P. aeruginosa to cancer cells and cancer invasion (Fig.
3). We will use the recA mutant as a bacterial SOS con-
trol because RecA initiates SOS that may facilitate
development of the adhesion-invasion phenotypes. We
will incubate these bacterial cells with cancer cells in
the presence of the anticancer drugs that inhibit DNA
replication enzymes including DNA polymerases [24],
DNA helicases [25], ribonucleotide reductases [23], and
topoisomerases [26]. We will harvest the invaded
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Figure 2 The hypothesis of bacterial cancer capture-invasion phenotypes. The bacterial SOS response is triggered by DNA damage caused
by treatment with replication inhibition anticancer drugs. If damage is so extensive that the cells cannot directly repair, the lesions of damage
can be bypassed, leading to mutagenesis and genetic instability. A variety of bacterial mutants can be generated consequently and selected for
adhesion to cancer cells and invade them to evade the drug attack. The mutants produce proteins (triangles) that recognize the cancer cells
surface (double triangles) and mediate bacterial adhesion to the cancer cells.
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teomic analysis to reveal proteins that exhibit distinct
changes in expression in the bacterial cells that adhere
to and invade into cancer cells. Lastly, according to the
proteomic results, we will identify the mutated genes
encoding cancer adhesion and invasion. We will con-
struct the deletion mutants by deletion-insertion of the
genes encoding the induced proteins. We will test the
mutants for cancer adhesion and invasion. We will
over-produce these proteins and examine adhesion-inva-
sion phenotypes against the cancer cells and the non-
cancer control.
Bacterial proteins differentially induced during bacteria-
cancer interaction
Bacteria under the anticancer drug-induced SOS are
expected to produce proteins that mediate the cancer
adhesion-invasion phenotypes (Figs. 2 and 3). The pro-
tein induction is generally reflected by alterations in the
intensities of the 2-D gel protein spots from the invaded
and non-invaded bacteria, with reference to the SOS
controls. Interacting with cancer cells, the bacteria are
likely to evolve a pattern of surface proteins suitable for
bacterial adhesion to and invasion of cancer cells (Fig.
2). The pattern is likely to be unique to the cancer
adhesion-invasion phenotypes as compared with that of
the SOS and non-invaded controls. These proteins are
expected to be deficient in the recA mutant, in which
SOS is precluded. They are unlikely to appear on the
non-invaded bacterial control.
Identification of bacterial genes encoding cancer
adhesion and invasion
It is plausible that knocking out the bacterial cancer-
adhesion-invasion genes would disrupt the adhesion-
invasion phenotypes. If the proteomic analysis indicates
increases in the levels of the proteins from the bacteria
with the adhesion-invasion phenotypes, mutations with
inactivation of the genes encoding these proteins will
render the mutant bacteria unable to attach to and
invade the cancer cells. However, over-production of
these proteins is expected to enhance bacterial capture
and invasion of the cancer cells but not the non-cancer
control. Then, it can be concluded that these genes are
required for the cancer adhesion-invasion phenotypes.
Collectively, the high resolution of the 2-D based pro-
teomic approach will allow us to identify the patterns of
the cancer-inducible surface proteins on bacteria so that
the encoding genes can be identified. These genes can
be cloned and expressed in non-pathogenic bacteria that
are safe to the hosts but selectively lethal to cancer cells.
Implications of the hypothesis
Our hypothesis regarding evolution of bacterial antican-
cer phenotypes implies that bacteria can evolve cancer
cell-specific phenotypes when growing with cancer cells
of certain types, for instance, the metastatic cells. Metas-
tasis is a process in which cancer cells migrate to distant
sites and adapt to the tissue microenvironment from the
primary cancer and thus becomes the major cause of
deaths in cancer patients. While metastasis can be
impaired by the antagonist bacterial biofilms [6] or by
the bacterial proteins [19-21] during treatment with the
anticancer drugs as proposed previously [6], the under-
lying mechanism for bacterial recognition or tropism for
cancer cells is not fully understood and thus addressed
by this hypothesis. As bacterial tropism is still in its
infancy, if this hypothesis is true, the outcomes may
Anticancer drug
The SOS response
Cancer cells
Proteomic analysis
Gene identification
Cloning and expression
Cancer capture & invasion
No action to normal cells
Bacterium
1)
2)
3)
4)
5)
Figure 3 Experimental design. 1) Examine bacterial attachment to
and invasion into cancer cells in the presence of the anticancer
drug that induces the SOS response. 2) Use proteomic analysis to
reveal the bacterial proteins that exhibit changes in expression. 3)
Identify the genes encoding cancer adhesion and invasion. 4)
Construct the mutants for the genes, clone and express these
genes. And 5) examine the bacterial capture and invasion of cancer
cells in contrast to non-cancer control.
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evolution of the bacterial tropism for cancer cells, con-
tributing to formulating novel bacterial anti-metastasis
regimens.
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